Mark Pepys, FMedSci, FRS | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Researchers
Mark Pepys, FMedSci, FRS

Mark Pepys, FMedSci, FRS

Researcher
Director
Wolfson Drug Discovery Unit
Centre for Amyloidosis & Acute Phase Proteins
University College London
Rowland Hill Street
London, United Kingdom
Mark Pepys is a Director of Wolfson Drug Discovery Unit Centre for Amyloidosis & Acute Phase Proteins and Clinical Research Associate in Department of Medicine at University College London (UCL). He is a physician and immunologist whose work on blood proteins has elucidated mechanisms of disease, identified new targets for treatment and led to improved diagnosis and treatments.
 
He invented a unique, non-invasive scan for diagnosis and monitoring of patients with amyloidosis, a fatal disease caused by accumulation of abnormal protein fibres in the tissues. His work has greatly improved understanding, management and outcome of the disease, and he founded the world-leading National Amyloidosis Centre, which serves patients from the United Kingdom and many from abroad.
 
Mark has also designed new therapeutic approaches for amyloidosis and Alzheimer’s disease. His treatment for amyloidosis is being developed by GlaxoSmithKline in collaboration with the Wolfson Drug Discovery Unit at UCL, and its clinical trial is providing positive results. 
 
 
Representative Publications:
 
 
 
 
view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close